EXICURE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
EXICURE, INC. (XCUR) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 84 shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2025-03-18
- EXICURE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2020-12-31 was 214.72K shares.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2020-09-30 was 491.29K shares.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2024 was 84.00 shares, a 99.81% decline from fiscal 2023.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2023 was 44.14K shares, a 87.04% decline from fiscal 2022.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2022 was 340.49K shares, a 75.11% decline from fiscal 2021.
- EXICURE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2021 was 1.37M shares, a 88.73% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | 84.00 shares 10-K · filed 2025-03-18 | ||||
| 2023-12-31 | 44.14K shares 10-K · filed 2025-03-18 | 220.72K shares 10-K · filed 2024-06-06 | |||
| 2022-12-31 | 340.49K shares 10-K · filed 2024-06-06 | ||||
| 2021-12-31 | 1.37M shares 10-K · filed 2022-03-25 | ||||
| 2020-12-31 | 214.72K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | 706.01K shares derived: sum of 2 quarters · filed 2021-03-11 | 724.76K shares 10-K · filed 2021-03-11 | ||
| 2020-09-30 | 491.29K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | 510.04K shares 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | 18.75K shares 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |